366 related articles for article (PubMed ID: 17061042)
1. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
5. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
[TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Wenzel C; Locker GJ; Schmidinger M; Rudas M; Taucher S; Gnant MF; Jakesz R; Steger GG
Anticancer Drugs; 2002 Jan; 13(1):67-74. PubMed ID: 11914643
[TBL] [Abstract][Full Text] [Related]
10. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
Bharat A; Gao F; Margenthaler JA
Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
[TBL] [Abstract][Full Text] [Related]
11. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
12. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating lobular carcinoma of the breast: systemic treatment.
Farese SA; Aebi S
Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
[TBL] [Abstract][Full Text] [Related]
14. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
[TBL] [Abstract][Full Text] [Related]
15. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
17. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
Karanlik H; Ozgur I; Cabioglu N; Sen F; Erturk K; Kilic B; Onder S; Deniz M; Yavuz E; Aydiner A
Eur J Surg Oncol; 2015 Sep; 41(9):1226-33. PubMed ID: 26141784
[TBL] [Abstract][Full Text] [Related]
19. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?
Jayasinghe UW; Bilous AM; Boyages J
Breast J; 2007; 13(5):479-85. PubMed ID: 17760669
[TBL] [Abstract][Full Text] [Related]
20. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?
Sinha PS; Bendall S; Bates T
Eur J Surg Oncol; 2000 Dec; 26(8):733-7. PubMed ID: 11087636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
